Coordination aspects of pharmacovigilance system adjustment in terms of the global COVID-19 pandemic
Abstract
The purpose is to overview the crucial pharmacovigilance system adjustment measures concerning COVID-19 widespread pandemic and enlightens main current aspects of pharmacovigilance system revamp.
Materials and methods. There were used common science theoretical methods (system analysis, generalization and systems approach); bibliographic method (elaboration of scientific related literature on topic).
Results. Revamping pharmacovigilance system requires being improved in regulatory capacities, the use of appropriate public-health-driven science-based and user-friendly technologies, including digital technologies, and innovations to expand access to quality medical and relevant information. These proposals can promote health by putting pharmacovigilance at the center of efforts to achieve a sustainable healthcare system that uses universal health coverage and the health-related Sustainable Development Goals.
Conclusion. Vaccine safety is very important for the success of any vaccination program. A robust vigilance system will help detect, report and prevent any adverse reactions associated with vaccination. Effective pharmacovigilance of the COVID-19 vaccine, when ready for use, will prevent any adverse events associated with the vaccine and dispel any unreasonable concerns among vaccine users.
References
Savytskyi, V.L., Ivanko, O.M., Kozak, N.D. et all (2020). Metodychni rekomendatsii shchodo profilaktyky, minimizatsii zakhvoriuvanosti osobovoho skladu ZS Ukrainy hostroiu respiratornoiu khvoroboiu, sprychynenoiu koronavirusom COVID-19 (druhe vydannia). K.: UVMA. 108. [In Ukrainian]
15 Drugs Being Tested to Treat COVID-19 and How They Would Work. Available at: https://www.nature.com/articles/d41591-020-00019-9.
Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems (2021) [Digital source]/ [Sunil Shrestha, Januka Khatri, Sujyoti Shakya et al.] // Drugs & Therapy Perspectives volume 37, P. 376–382 (2021). – Mode of access: https://link.springer.com/article/10.1007/s40267-021-00852-z – Name from screen.
Beninger P. (2021). Influence of COVID-19 on the Pharmacovigilance Workforce of the Future. Clinical therapeutics, 43(2), 369–371. https://doi.org/10.1016/j.clinthera.2020.12.019
Bikash Ranjan Meher Need of Vibrant Vaccine Pharmacovigilance During Current Global COVID-19 Pandemic: More Than Ever. (2021). [Digital source]. Published online 2021 Feb 18. doi: 10.4103/jpbs.JPBS_416_20. – Mode of access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142916/ – Name from screen.
Bisetto, L.H., Ciosak, S.I. (2017). Analysis of adverse events following immunization caused by immunization errors. Rev Bras Enferm. 70, 87-95.
Chakraborty, I., & Maity, P. (2020). COVID-19 outbreak: Migration, effects on society, global environment and prevention. The Science of the total environment, 728, 138882. https://doi.org/10.1016/j.scitotenv.2020.138882
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment). (2021) – Mode of access: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. – Name from screen.
Pathak, S., Singh, R., Saraf, S.A. (2021). COVID-19: An Opportunity to Revamp Pharmacovigilance System RIS Discussion Papers. 32. https://www.researchgate.net/profile/Rajeshwari-Singh/publication/355712958_COVID_-19_An_Opportunity_to_Revamp_Pharmacovigilance_System_RIS_Discussion_Paper_Series/links/617ac7e43c987366c3f868cf/COVID-19-An-Opportunity-to-Revamp-Pharmacovigilance-System-RIS-Discussion-Paper-Series.pdf
Dhama, K., Patel, S. K., Sharun, K., Pathak, M., Tiwari, R., Yatoo, M. I., Malik, Y. S., Sah, R., Rabaan, A. A., Panwar, P. K., Singh, K. P., Michalak, I., Chaicumpa, W., Martinez-Pulgarin, D. F., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020). SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel medicine and infectious disease, 37, 101830. https://doi.org/10.1016/j.tmaid.2020.101830
Draft Landscape of COVID-19 Candidate Vaccines. (2021). – Mode of access: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. – Name from screen.
Han, S. (2015). Clinical vaccine development. Clinical and experimental vaccine research, 4(1), 46–53. https://doi.org/10.7774/cevr.2015.4.1.46
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process (2021). [Digital source]. – Mode of access: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf – Name from screen.
Vaccines. (2021). – Mode of access: https://www.who.int/topics/vaccines/en/– Name from screen.
WHO Coronavirus Disease (COVID-19) Dashboard. ). – Mode of access: https://covid19.who.int/ (2021). – Name from screen.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W., & China Novel Coronavirus Investigating and Research Team (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMoa2001017
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
